Martin Auster
Stock Analyst at Raymond James
(4.26)
# 354
Out of 5,182 analysts
52
Total ratings
58.54%
Success rate
14.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Strong Buy | $40 | $23.72 | +68.63% | 1 | Jan 8, 2026 | |
| SEPN Septerna | Initiates: Strong Buy | $38 | $25.18 | +50.91% | 1 | Dec 19, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Outperform | $69 → $71 | $73.15 | -2.94% | 2 | Oct 30, 2025 | |
| IRON Disc Medicine | Maintains: Strong Buy | $89 → $108 | $65.18 | +65.70% | 1 | Oct 17, 2025 | |
| ASND Ascendis Pharma | Initiates: Strong Buy | $271 | $229.25 | +18.21% | 1 | Oct 17, 2025 | |
| DYN Dyne Therapeutics | Upgrades: Strong Buy | $31 → $35 | $18.84 | +85.77% | 2 | Aug 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $318.85 | +32.98% | 2 | Aug 1, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $55.50 | +116.22% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $22.45 | +367.71% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $8.04 | +223.38% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $120 | $7.49 | +1,502.14% | 4 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $58 | $32.74 | +77.15% | 3 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $169 → $196 | $564.81 | -65.30% | 4 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $98 | $1.97 | +4,874.62% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $162.43 | -63.06% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $50.01 | +29.97% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $23.23 | +214.25% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $17.16 | +354.55% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.61 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $8.61 | +399.42% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $13.13 | +59.94% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $57.68 | -72.26% | 1 | May 7, 2020 |
Evommune
Jan 8, 2026
Initiates: Strong Buy
Price Target: $40
Current: $23.72
Upside: +68.63%
Septerna
Dec 19, 2025
Initiates: Strong Buy
Price Target: $38
Current: $25.18
Upside: +50.91%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Outperform
Price Target: $69 → $71
Current: $73.15
Upside: -2.94%
Disc Medicine
Oct 17, 2025
Maintains: Strong Buy
Price Target: $89 → $108
Current: $65.18
Upside: +65.70%
Ascendis Pharma
Oct 17, 2025
Initiates: Strong Buy
Price Target: $271
Current: $229.25
Upside: +18.21%
Dyne Therapeutics
Aug 25, 2025
Upgrades: Strong Buy
Price Target: $31 → $35
Current: $18.84
Upside: +85.77%
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $318.85
Upside: +32.98%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $55.50
Upside: +116.22%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $22.45
Upside: +367.71%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $8.04
Upside: +223.38%
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $7.49
Upside: +1,502.14%
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $32.74
Upside: +77.15%
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $564.81
Upside: -65.30%
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $1.97
Upside: +4,874.62%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $162.43
Upside: -63.06%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $50.01
Upside: +29.97%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $23.23
Upside: +214.25%
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $17.16
Upside: +354.55%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $2.61
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $8.61
Upside: +399.42%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $13.13
Upside: +59.94%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $57.68
Upside: -72.26%